Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
A Century of Schizophrenia: One Disorder or Many?
2.
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer
3.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
4.
Mental health risk persists years after cancer diagnosis
5.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
1.
The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide
2.
Machine Learning for Bone Marrow Ecosystem Analysis
3.
Understanding Lymphedema: Symptoms, Causes, and Treatment
4.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
5.
Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
2.
Oropharyngeal Cancer in Relation to HPV Status
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation